PHARNEXT
Created in 2007
- BETA
To investigate (B)
Some signals may appear as inconsistent with a regular activity Social networks
3,059 4,289Activities
Technologies
Entity types
Location
14 Rue de la République, 92150 Suresnes, France
Suresnes
France
Employees
Scale: 11-50
Estimated: 22
SIREN
691124424Engaged corporates
5
4 2Added in Motherbase
6 years, 4 months ago
biotech Value proposition
New therapies for neurodegenerative diseases
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships. Both of Pharnext’s lead assets originated from the PleotherapyTM R&D approach. Pharnext draws the attention of investors to the financial and other risk factors detailed in its financial reports. More information can be found at www.pharnext.com.
Pharnext is listed on the Euronext Growth Stock Exchange in Paris.
Maladies neurodégénératives, Développement de molécules, and études cliniquesOriginal language
New therapies for neurodegenerative diseases
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships. Both of Pharnext’s lead assets originated from the PleotherapyTM R&D approach. Pharnext draws the attention of investors to the financial and other risk factors detailed in its financial reports. More information can be found at www.pharnext.com.
Pharnext is listed on the Euronext Growth Stock Exchange in Paris.
- https://pharnext.com/
- Website is disabled or domain is for sale
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 9 Jan 2024 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Other 3 Nov 2016 | | |
 Euronext Finance, Financial Services | Euronext Finance, Financial Services | Other 13 Feb 2018 | | |
 Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Other 21 Jan 2019 | | |
 Genopole Biotechnology, Biotechnology Research | Genopole Biotechnology, Biotechnology Research | Not capitalistic Partnership Not event 31 Aug 2020 | | |